FIGURE 2.

Choice of systemic first‐line treatment in marginal zone lymphoma. First‐line treatments/treatment combinations between 2009 and 2014 sorted by relative frequency for (A) all patients included (n = 175) and (B) classified into either MALT MZL (n = 58) or non‐MALT MZL (n = 117). Bendamustine‐based: bendamustine (±prednisone), bendamustine + rituximab (±prednisone)^a, bendamustine + vincristine (±prednisone/ rituximab); chlorambucil‐based: chlorambucil (mono), chlorambucil + rituximab; fludarabine‐based: fludarabine + cyclophosphamide (±rituximab); CHOP‐based: CHOP or COP + rituximab; other: R‐CHO(P)/R‐DHAP, dexamethasone + methotrexate, trofosfamide + rituximab + prednisone. Note: Percentages may not add up to 100% due to rounding. CHO(P), cyclophosphamide/doxorubicin/vincristine/(prednisone); COP, cyclophosphamide/vincristine/prednisone; DHAP, dexamethasone/high‐dose cytarabine (Ara‐C)/cisplatin; MALT, mucosa‐associated lymphoid tissue; MZL, marginal zone lymphoma; R, rituximab.^a One patient switched to bendamustine + rituximab after one cycle of R‐CHOP